Last updated: September 23, 2026
Orudis is the former U.S. prescription brand for ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID) used for pain and arthritis. The brand has lost commercial relevance because its active ingredient entered a mature generic market, historical patent protection expired, and the branded product is no longer a meaningful revenue contributor. Current commercial activity is concentrated in generic ketoprofen capsules, extended-release ketoprofen products historically marketed as Oruvail, and non-U.S. formulations.
What is Orudis and who marketed it?
Orudis contains ketoprofen, a propionic-acid NSAID related to ibuprofen and naproxen. It was marketed in the United States for osteoarthritis, rheumatoid arthritis, and acute pain.
| Attribute |
Orudis |
| Active ingredient |
Ketoprofen |
| Drug class |
Nonselective NSAID |
| Original dosage forms |
Immediate-release capsules |
| Historical strengths |
25 mg, 50 mg, and 75 mg |
| Historical U.S. sponsor |
Wyeth-Ayerst Laboratories and predecessor organizations |
| Extended-release brand |
Oruvail |
| Current U.S. brand status |
Commercially discontinued |
| Generic status |
Ketoprofen products have been available as generic prescription drugs |
| Biosimilar exposure |
None |
| Primary competitors |
Ibuprofen, naproxen, diclofenac, meloxicam, celecoxib |
Orudis competed in a large but highly commoditized pain and arthritis market. Its clinical differentiation was limited. Prescribers could select from multiple low-cost NSAIDs, while generic ibuprofen and naproxen had extensive retail availability.
When did Orudis lose exclusivity?
Orudis lost meaningful market exclusivity decades ago. The product entered a generic market after expiration of its original patent protection and any applicable regulatory exclusivity.
The commercial sequence was typical for an older small-molecule medicine:
- Ketoprofen was commercialized as a prescription anti-inflammatory.
- Orudis developed brand recognition in pain and arthritis treatment.
- Generic ketoprofen became available.
- Payers shifted utilization toward lower-cost alternatives.
- The branded product was discontinued or ceased to have material sales.
- Generic ketoprofen remained available in limited and declining prescription channels.
The original Orudis patent estate is no longer a barrier to generic entry. No active patent portfolio is known to preserve branded U.S. exclusivity for immediate-release ketoprofen capsules.
What is the FDA regulatory status of Orudis?
Orudis is not a growth product in the current U.S. pharmaceutical market. The branded product is listed as discontinued rather than commercially active in current FDA product databases.
U.S. regulatory pathway
Ketoprofen was approved through the conventional new drug application pathway. Generic versions were subsequently approved under abbreviated new drug applications (ANDAs), relying on the reference product’s safety and efficacy findings.
The FDA regulatory profile is now defined by:
- Historical approval of the branded reference product.
- Generic ANDA approvals for ketoprofen.
- No current branded innovation program.
- No biologic license application.
- No biosimilar pathway.
- No major pending clinical-development program tied to Orudis.
The regulatory burden for generic manufacturers is primarily bioequivalence, manufacturing compliance, stability, labeling, and supply reliability.
What is the Orange Book status of Orudis?
The Orange Book historically identified Orudis as a reference drug for ketoprofen products. The current commercial importance of the listing is limited because the relevant exclusivity period and patent protection have expired.
| Orange Book issue |
Orudis assessment |
| Reference listed drug status |
Historical reference product |
| Active brand sales |
No meaningful current U.S. branded sales |
| Listed patents blocking generic entry |
No commercially relevant active patent barrier identified |
| Paragraph IV exposure |
Historical or product-specific rather than a current branded threat |
| Current generic availability |
Yes, subject to manufacturer and supply conditions |
| Regulatory exclusivity |
Expired |
The Orange Book does not create continuing exclusivity for a discontinued, mature small-molecule product. Its principal current value is historical and regulatory, including reference-product identification and generic approval context.
What patents protect Orudis?
No active patent estate is known to protect the original Orudis product in the United States.
Historical patent protection
The original ketoprofen intellectual-property position likely covered the active compound and early pharmaceutical use. Those rights expired long before the current generic market matured. Any historical compound patent would have been subject to the ordinary term applicable at the time of filing, rather than the 20-year term used for newer U.S. patent applications.
Later protection could have involved:
- Immediate-release capsule formulations.
- Extended-release ketoprofen delivery.
- Manufacturing processes.
- Specific dosage regimens.
- Salt, crystal, or excipient systems.
- Combination products.
These categories did not preserve meaningful exclusivity for Orudis as a branded product.
Formulation patents
Extended-release ketoprofen was commercialized separately under the Oruvail brand. Formulation and controlled-release patents may have delayed generic competition for particular extended-release products, but those rights are expired or commercially exhausted.
Formulation patents do not restore protection to immediate-release Orudis capsules. A generic manufacturer can enter with a formulation that satisfies the applicable bioequivalence and labeling requirements without practicing an expired controlled-release claim.
Method-of-use patents
Ketoprofen’s uses in pain, osteoarthritis, and rheumatoid arthritis are established therapeutic indications. Any historical method-of-use claims are no longer commercially effective as exclusivity tools. Generic labels may use appropriate carve-outs where a patent-protected indication exists, but that issue is not material to the former Orudis franchise.
How many patents cover Orudis today?
No active U.S. patent portfolio is known to block generic ketoprofen entry or support a current Orudis franchise.
The relevant distinction is between:
- Historical patents associated with ketoprofen or Orudis.
- Expired patents associated with formulation or extended release.
- Active patents that could block current generic products.
For Orudis, the third category is effectively empty. The product has no defensible patent moat comparable with a recently launched branded medicine.
Which companies challenged Orudis exclusivity?
Generic competition came from manufacturers of ketoprofen capsules and related dosage forms rather than from a current litigation campaign against an active Orudis brand.
The competitive field has included generic pharmaceutical companies that supply oral NSAIDs to wholesalers, pharmacies, hospitals, and government purchasers. Manufacturer participation can vary because ketoprofen is a low-margin product with modest demand and limited commercial incentives.
Relevant competitors include generic suppliers such as:
- Teva Pharmaceutical Industries.
- Sandoz and other Novartis generic operations.
- Mylan, now part of Viatris.
- Taro Pharmaceutical Industries.
- West-Ward, now associated with Hikma operations.
- Other FDA-approved ANDA holders and contract manufacturers.
Product availability has not been uniform. A manufacturer may retain an approved ANDA while producing intermittently or discontinuing a product because of low volume, manufacturing costs, or supply-chain constraints.
What patent litigation affects Orudis?
No current high-value patent litigation is associated with Orudis.
The product’s litigation exposure is materially different from that of newer branded drugs:
| Litigation category |
Current relevance |
| Paragraph IV litigation |
Low |
| Brand-versus-generic patent litigation |
No material current dispute identified |
| Formulation patent litigation |
Historical and commercially exhausted |
| Product liability litigation |
Potentially relevant to NSAID risk, but separate from exclusivity |
| Antitrust litigation |
No material current Orudis-specific controversy identified |
| Biosimilar litigation |
Not applicable |
The main legal risks for manufacturers are ordinary product liability, labeling, manufacturing, and supply obligations rather than patent enforcement.
How strong is the Orudis patent estate?
The current patent estate is weak from a commercial perspective.
| Patent-estate factor |
Assessment |
| Compound protection |
Expired |
| Immediate-release formulation protection |
Expired |
| Extended-release protection |
Expired or no longer commercially decisive |
| Method-of-use protection |
Expired or nonblocking |
| Patent-term extension value |
None of current commercial significance |
| Freedom-to-operate for generic capsules |
Broad |
| Ability to support premium pricing |
None |
| Litigation leverage |
Minimal |
Orudis has no active exclusivity mechanism capable of supporting premium pricing. The only possible barriers are operational: manufacturing validation, supplier qualification, inventory economics, and demand forecasting.
What generic entry risks exist?
Generic entry has already occurred. The current issue is not whether generics can enter, but whether manufacturers will continue supplying the product consistently.
Generic launch scenarios
Base case: continued low-volume supply
Generic ketoprofen remains available through a limited number of manufacturers. Pricing stays low, and supply fluctuates with demand.
Downside case: supply contraction
One or more manufacturers exit because of low profitability. A smaller supplier base increases the risk of temporary shortages and price volatility.
Upside case: limited re-commercialization
A generic company could reintroduce or expand ketoprofen supply if a distributor identifies institutional or specialty demand. This would not recreate branded Orudis economics.
A large generic launch is unlikely because ketoprofen lacks strong growth drivers, differentiated delivery technology, or meaningful pricing power.
How does Orudis compare with competing NSAIDs?
Orudis is commercially weaker than most major NSAID alternatives.
| Drug |
Brand or generic position |
Competitive advantage |
Market status |
| Ketoprofen |
Primarily generic |
Established NSAID efficacy |
Mature, low-volume |
| Ibuprofen |
Advil, Motrin, generic |
OTC access, broad consumer awareness |
Large and highly competitive |
| Naproxen |
Aleve, generic |
Longer dosing interval |
Large OTC and prescription market |
| Diclofenac |
Voltaren, generic |
Multiple topical and oral formulations |
Broad generic and topical presence |
| Meloxicam |
Mobic, generic |
Once-daily prescription dosing |
Established prescription market |
| Celecoxib |
Celebrex, generic |
COX-2 selectivity and GI positioning |
Larger branded history and generic base |
Ketoprofen has no major current formulation advantage over these products. Its strongest remaining rationale is physician familiarity and individual patient response, not market differentiation.
What is the financial trajectory for Orudis?
Orudis no longer generates a meaningful standalone revenue stream for its historical sponsor. Public company reporting generally does not provide current product-level revenue for a discontinued mature brand.
Financial trajectory
| Period |
Commercial condition |
Financial implication |
| Launch and early adoption |
Branded prescription NSAID |
Revenue supported by brand pricing |
| Generic-entry period |
Multiple competing products |
Rapid price and share erosion |
| Mature generic period |
Low-cost substitution |
Margins compressed |
| Discontinuation period |
Brand withdrawn or inactive |
Branded revenue approaches zero |
| Current period |
Generic supply only |
Revenue fragmented across manufacturers |
The product’s economic value is now residual. A manufacturer may earn small revenue from generic capsules, but the category does not support the sales force, promotional spending, or pricing structure associated with an active branded medicine.
Revenue exposure
For a former sponsor such as Wyeth, Orudis is not expected to be a material contributor to current revenue. Its financial impact is more likely to appear through:
- Historical product revenue.
- Legacy product liability.
- Discontinued-product manufacturing obligations.
- Portfolio rationalization.
- Generic or divestiture arrangements.
No reliable public estimate supports a current standalone Orudis revenue figure. Any valuation that assigns material present value to the brand would be inconsistent with its discontinued status and expired exclusivity.
What licensing deals affected Orudis?
Orudis was associated historically with multinational pharmaceutical commercialization and legacy brand portfolios. Product rights for older NSAIDs often moved through corporate acquisitions, licensing arrangements, and portfolio transfers.
Current licensing value is limited because:
- The active ingredient is generic.
- No meaningful U.S. patent barrier remains.
- Brand demand is weak.
- Generic suppliers can compete without licensing the former brand.
- There is no known modern platform technology attached to Orudis.
Any remaining commercial arrangement would likely concern local distribution, regulatory maintenance, or legacy inventory rather than strategic global licensing.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are more important than patent barriers.
Manufacturing issues
Generic ketoprofen manufacturers must manage:
- Active pharmaceutical ingredient sourcing.
- Impurity and stability control.
- Capsule-filling capacity.
- Quality-system compliance.
- Bioequivalence documentation.
- Packaging and serialization.
- Small-batch economics.
- Wholesale inventory requirements.
The product’s low price can make supply vulnerable to cost increases. A manufacturer may discontinue a low-volume dosage strength even when the product remains approved.
Geographic coverage
Ketoprofen is marketed in multiple international jurisdictions, but brand names, formulations, and regulatory status vary. Orudis may be absent from certain markets even where ketoprofen remains available under another brand or as a generic.
The strongest commercial distinction is between:
- The United States, where Orudis is a discontinued legacy brand.
- Europe and other markets, where ketoprofen may remain available under national brands.
- Markets where topical ketoprofen products have greater relevance than oral capsules.
- Regions where prescription NSAID substitution is driven primarily by local reimbursement policy.
U.S. patent expiry does not determine commercial status in other jurisdictions. Each market requires separate review of national registrations, local patents, and marketing authorizations.
What is the outlook for Orudis?
The outlook is stable-to-declining for the brand and low-value for generic suppliers.
The most likely market structure is:
- No branded relaunch.
- No new patent-backed product cycle.
- Continued generic availability where demand supports supply.
- Limited revenue per manufacturer.
- Occasional shortages caused by supplier exits.
- Competitive pressure from ibuprofen, naproxen, diclofenac, meloxicam, and celecoxib.
- Greater commercial relevance for topical ketoprofen than for the original Orudis brand in some markets.
Orudis could have strategic value only as a low-cost portfolio product, a registered product in an underserved market, or part of a broader generic NSAID offering. It does not present an attractive standalone licensing or acquisition target based on brand equity or intellectual property.
Key Takeaways
- Orudis is a legacy ketoprofen brand with no meaningful current U.S. branded revenue.
- Generic ketoprofen entered the market after expiration of the relevant original patent protection.
- No active U.S. patent estate is known to block generic immediate-release ketoprofen.
- Historical extended-release and formulation rights associated with Oruvail are not current commercial barriers.
- Paragraph IV litigation and biosimilar risk are not material to the product.
- Current economics are determined by generic manufacturing cost, supply reliability, and limited demand.
- The principal competitors are ibuprofen, naproxen, diclofenac, meloxicam, and celecoxib.
- Any current value lies in generic supply or regional registrations, not in the Orudis brand.
FAQs About Orudis Ketoprofen
Is Orudis still available in the United States?
The branded Orudis product is commercially discontinued in the United States. Generic ketoprofen may remain available depending on manufacturer supply and dosage form.
Is ketoprofen still protected by patents?
The original ketoprofen compound and legacy Orudis product protections have expired. No active patent barrier is known to prevent generic ketoprofen competition in the United States.
Is Orudis the same as Oruvail?
No. Both products contain ketoprofen, but Orudis was associated with immediate-release capsules, while Oruvail was an extended-release formulation.
Can a company relaunch Orudis?
A company could seek regulatory approval and commercial rights for a product using the Orudis name if available, but a relaunch would face generic competition, limited pricing power, and weak brand demand.
Does Orudis have biosimilar competition?
No. Orudis is a small-molecule drug, not a biologic. Its relevant competitors are generic ketoprofen products and other generic or branded NSAIDs.
References
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). ANDA approvals and generic drugs. https://www.fda.gov/drugs/generic-drugs
-
U.S. National Library of Medicine. (n.d.). DailyMed: Ketoprofen drug labeling. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2015). FDA drug safety communication: FDA strengthens warning that non-aspirin NSAIDs increase chance of heart attack or stroke. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers
-
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term expiration. https://www.uspto.gov/patents/laws/patent-term-adjustment-patent-term-calculator
